Skip to content

Study on the clinical efficacy of Yiqi Huoxue Jiedu formula in the treatment of platinum resistant ovarian cancer based on the phenotypic changes of macrophages

Study on the clinical efficacy of Yiqi Huoxue Jiedu formula in the treatment of platinum resistant ovarian cancer based on the phenotypic changes of macrophages

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100051316
Enrollment
Unknown
Registered
2021-09-18
Start date
2021-05-25
Completion date
Unknown
Last updated
2022-06-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ovarian cancer

Interventions

Sponsors

Guang'anmen Hospital, Chinese Academy of traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Patients with primary epithelial ovarian cancer were diagnosed by surgical pathology; 2. Relapse within 6 months after the last platinum based chemotherapy withdrawal, or progress during chemotherapy; 3. The syndrome type of traditional Chinese medicine is Qi deficiency and blood stasis syndrome. The syndrome differentiation refers to the guiding principles for clinical research of new traditional Chinese medicine. The Qi deficiency syndrome and blood stasis syndrome are completed under the guidance of the chief physician of traditional Chinese medicine. Qi deficiency syndrome: it is necessary to differentiate between light tongue, light fat tongue, tooth marks on the edge of light tongue and two of shortness of breath, fatigue, spontaneous sweating, weak pulse or weak pulse; Blood stasis syndrome: facial ecchymosis, pain, precordial pain, limb numbness, hemiplegia, wrong skin nail, dark complexion, menstrual blood clot, dark tongue, ecchymosis, blue and purple sublingual vein. Syndrome differentiation can be achieved if there are 2 or more; 4. ECoG score: 0-1; 5. Estimated survival time >= 2 months; 6. Sign informed consent.

Exclusion criteria

Exclusion criteria: 1. Previous history of other tumors; 2. those with infectious diseases or immune system diseases have not yet been controlled; 3. Recent use of immunosuppressants; 4. Suffering from serious heart, liver, kidney and hematopoietic diseases without control; 5. Accompanied by mental illness, severe neurological deficit (such as aphasia and agnosia) or unable to cooperate with the investigation due to other reasons; 6. Those who are allergic to the drugs in this prescription.

Design outcomes

Primary

MeasureTime frame
IL6;M2;

Countries

China

Contacts

Public ContactWu Xiaoqing

Guang'anmen Hospital, Chinese Academy of Traditional Chinese Medicine

673498069@qq.com+86 13121682053

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026